Isolation, characterization and HepG-2 inhibition of a novel proteoglycan from Flammulina velutipes.

Int J Biol Macromol

Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology and Business University, Beijing 100048, China; Key Laboratory of Grains and Oils Quality Control and Processing, Collaborative Innovation Center for Modern Grain Circulation and Safety, College of Food Scienc

Published: October 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Flammulina velutipes has anti-inflammatory, immunomodulatory, antioxidant and many bioactive properties with high contents of carbohydrate, proteins and fibers. In this study, a novel proteoglycan with polysaccharide complexes and protein chain, named PGD1-1, was isolated from F. velutipes. The structural characteristics of PGD1-1 were then determined, and its anti-proliferation and pro-apoptotic activities against HepG-2 cells were demonstrated in vitro. Results proved that the average molecular weight of PGD1-1 was 32.71 kDa, and the carbohydrate and protein contents were 93.35 and 2.33%, respectively. The protein moiety was bonded to a polysaccharide chain via O-glycosidic linkage. The monosaccharides consisted of d-glucose, D-galactose and D-xylose in a molar ratio of 21.90:2.84:1.00. PGD1-1 significantly inhibited the proliferation of HepG-2 cells by affecting cell lipid peroxidation and nitric oxide production. In addition, PGD1-1 promoted the apoptosis of HepG-2 cells, especially the early apoptosis. These findings proved that PGD1-1 was a novel potent ingredient against the proliferation of HepG-2, which will provide a theoretical basis for the development and utilization of the functional ingredients of the F. velutipes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2021.08.086DOI Listing

Publication Analysis

Top Keywords

hepg-2 cells
12
novel proteoglycan
8
flammulina velutipes
8
proliferation hepg-2
8
pgd1-1
6
hepg-2
5
isolation characterization
4
characterization hepg-2
4
hepg-2 inhibition
4
inhibition novel
4

Similar Publications

Background: This study seeks to provide preclinical evidence demonstrating the potential of Antrocinol, a derivative of antrocin derived from the active compound of Antrodia cinnamomea, as a promising small-molecule drug candidate for overcoming drug-resistant hepatocellular carcinoma (HCC).

Methods: We developed Lenvatinib-resistant Huh-7 and HepG cell lines (Huh-7/LR, HepG2/LR) to evaluate their viability and apoptotic response to Antrocinol. Autophagy-dependent cell death was assessed in Huh-7/LR cells using Z-VAD-FMK and shATG5 transfection.

View Article and Find Full Text PDF

The chemical constituents from Cephalotaxus lanceolata were isolated and purified by using multiple chromatographic techniques, including octadecylsilane(ODS), silica gel, Sephadex LH-20 column chromatography, and semi-preparative high-performance liquid chromatography(HPLC). A total of 17 compounds obtained were identified by using spectroscopic methods such as nuclear magnetic resonance(NMR), mass spectrometry(MS), and ultraviolet(UV) combined with literature data. Compound 1 was a new alkaloid dimer, named cephalancetine E.

View Article and Find Full Text PDF

Background: Vascular endothelial growth factor receptor-2 (VEGFR-2) is a validated target in cancer therapy. However, approved inhibitors like sorafenib are often limited by off-target toxicity and resistance. This study aimed to develop novel thiadiazole-based VEGFR-2 inhibitors with improved selectivity and safer profiles.

View Article and Find Full Text PDF

A novel series of quinazoline-based compounds were designed and synthesized as modified analogues to certain known VEGFR-2 inhibitors, as an extension of our work on the design and synthesis of new VEGFR-2 inhibitors. The anti-proliferative properties of the synthesized compounds were assessed against three tumor cell lines (MCF-7, HepG-2, and K-562). Compounds 8a (IC = 0.

View Article and Find Full Text PDF

A series of hybrid molecules 6a-6d-13a-13d combining pyrazolo[3,4-]pyrimidine or aminopurine frameworks with an oxindole moiety were designed as multitarget anticancer agents. Several compounds, especially 8b and 12a-12d, showed potent antiproliferative effects against three human cancer cell lines: A498 (kidney carcinoma), HepG-2 (hepatocellular carcinoma), and MDA-MB-231 (breast adenocarcinoma). Compounds 6b, 7b, 8b, and 12a-12c exhibited remarkable CDK6 inhibition (pIC of up to 7.

View Article and Find Full Text PDF